[go: up one dir, main page]

WO2004089414A3 - Combinaison de medicaments, association de medicaments et medicament - Google Patents

Combinaison de medicaments, association de medicaments et medicament Download PDF

Info

Publication number
WO2004089414A3
WO2004089414A3 PCT/BR2004/000046 BR2004000046W WO2004089414A3 WO 2004089414 A3 WO2004089414 A3 WO 2004089414A3 BR 2004000046 W BR2004000046 W BR 2004000046W WO 2004089414 A3 WO2004089414 A3 WO 2004089414A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
proton pump
blockers
combinations
prokinetic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2004/000046
Other languages
English (en)
Other versions
WO2004089414A2 (fr
Inventor
Negrao Alexandre Funari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medley Farmaceutica Ltda
Original Assignee
Medley Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medley Farmaceutica Ltda filed Critical Medley Farmaceutica Ltda
Publication of WO2004089414A2 publication Critical patent/WO2004089414A2/fr
Publication of WO2004089414A3 publication Critical patent/WO2004089414A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne une combinaison de médicaments, une association de médicaments, un médicament et un médicament ayant une présentation facilitée, qui comprend séparément et en même temps conjointement: une ou plusieurs unités de médicament renfermant un ou plusieurs agents inhibiteurs de la pompe à protons; une ou plusieurs unités de médicaments renfermant un ou plusieurs agents procinétiques; et éventuellement d'autres additifs ou médicaments qui sont bien connus des spécialistes, mélangés à un milieu ou à un excipient, également acceptable sur le plan pharmaceutique, servant de préférence au traitement de la dyspepsie fonctionnelle et du reflux gastro-oesophagien pathologique.
PCT/BR2004/000046 2003-04-08 2004-03-31 Combinaison de medicaments, association de medicaments et medicament Ceased WO2004089414A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0301179-8 2003-04-08
BR0301179 2003-04-08

Publications (2)

Publication Number Publication Date
WO2004089414A2 WO2004089414A2 (fr) 2004-10-21
WO2004089414A3 true WO2004089414A3 (fr) 2004-12-16

Family

ID=33136632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2004/000046 Ceased WO2004089414A2 (fr) 2003-04-08 2004-03-31 Combinaison de medicaments, association de medicaments et medicament

Country Status (1)

Country Link
WO (1) WO2004089414A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0303794A (pt) * 2003-09-05 2005-04-12 Medley S A Ind Farmaceutica Medicamento, kit de medicamentos, conjunto de medicamentos, associação medicamentosa e medicamento apresentando forma de apresentação facilitada

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0803251A1 (fr) * 1996-04-23 1997-10-29 Janssen Pharmaceutica N.V. Formes solides d'administration de cisapride à libération immédiate et indépendente du PH
WO2000051584A2 (fr) * 1999-03-02 2000-09-08 Sepracor Inc. Procedes et compositions destines a l'utilisation de norcisapride (-) en combinaison avec des inhibiteurs de pompes a protons ou des antagonistes du recepteur de h¿2?
WO2003097011A1 (fr) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions et methodes utilisant des inhibiteurs de la pompe a protons

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0803251A1 (fr) * 1996-04-23 1997-10-29 Janssen Pharmaceutica N.V. Formes solides d'administration de cisapride à libération immédiate et indépendente du PH
WO2000051584A2 (fr) * 1999-03-02 2000-09-08 Sepracor Inc. Procedes et compositions destines a l'utilisation de norcisapride (-) en combinaison avec des inhibiteurs de pompes a protons ou des antagonistes du recepteur de h¿2?
WO2003097011A1 (fr) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions et methodes utilisant des inhibiteurs de la pompe a protons

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANON.: "Refluxkrankheit der Speiseröhre und peptisches Ulkus", FORTSCHRITTE DER MEDIZIN, vol. 116, no. 34, 1998, pages 35 - 38, XP008037882 *
BEERS ET AL, EDS.: "The Merck Manual of Diagnosis and Therapy", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, NJ, USA, XP002303226 *
DE MORHAES-FILHO AND CHINZON: "Doença do refluxo gastroesofagico", REV. BRAS. MED., vol. 51, 1994 - 1995, pages 112 - 124, XP008037884 *
MATHESON AND JARVIS: "Lansoprazole - an update of its place in the management of acid-related disorders", DRUGS, vol. 61, no. 12, 2001, pages 1801 - 1833, XP008037879 *
MONES ET AL: "Criteria used by general practitioners in prescribing prokinetic or antisecretory drugs in patients with functional dyspepsia", REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, vol. 93, no. 5, 2001, pages 287 - 292, XP008037880 *
THJODLEIFSSON: "Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors", DRUGS AGING, vol. 19, no. 12, 2002, pages 911 - 927, XP008037878 *

Also Published As

Publication number Publication date
WO2004089414A2 (fr) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2005082414A3 (fr) Médicaments associés
WO2005044199A3 (fr) Combinaison d'un inhibiteur de pompe a protons et d'un agent favorisant le sommeil
TW200716678A (en) Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006071762A3 (fr) Inhibiteurs de dipeptidyl-peptidase iv a base de pyrimidine et methodes associees
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
ITBO20030062A1 (it) Capsula utilizzabile per la preparazione di una bevanda infusa.
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
WO2006041773A3 (fr) Composes a base de lactame utiles en tant qu'inhibiteurs de la proteine kinase
WO2007093450A3 (fr) Derives de catecholamine deuteries et medicaments comprenant de tels composes
WO2004030611A3 (fr) Inhibiteurs non nucleosidiques de transcriptases inverses
WO2007106317A3 (fr) Associations comprenant un ou des inhibiteur(s) de la protease de l'hcv et un ou des inhibiteur(s)de l'ires de l'hcv, et procedes therapeutiques apparentes
WO2005105088A3 (fr) Procedes d'utilisation et compositions comportant des composes immunomodulateurs pour le traitement et le controle de l'hypertension pulmonaire
UA101313C2 (uk) Щотижневе введення інгібіторів дипептидилпептидази
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
WO2006058007A3 (fr) Procedes et compositions permettant d'utiliser des inhibiteurs jnk pour traiter et gerer une blessure du systeme nerveux central
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
WO2004071374A3 (fr) Compositions pharmaceutiques d'administration orale une fois par jour
WO2007099171A3 (fr) Bicyclopyrazoles actifs comme inhibiteurs de la kinase
WO2005016249A3 (fr) Compositions constituees d'un inhibiteur chromene ou acide phenylacetique selectif de la cyclooxygenase-2 et d'un inhibiteur de ace pour traiter les lesions du systeme nerveux central
WO2005075471A3 (fr) Composes thiazole utilises en tant qu'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2008009802A3 (fr) Medicaments comprenant un inhibiteur des alpha-mannosidases de classe i pour le traitement des sarcoglycanopathies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase